In conclusion, SC144 represents a novel anti-cancer drug that induces transcription of genes involved in hypoxic stress, up-regulation of HIF1A-AS2, and activates a series of important signaling events responsible for cytotoxicity and immune activation. This evidence concerns the gene HIF1A and cancer.